G
Genmab A/S (GMAB)
NMS – Real Time Price. Currency in USD
27.09
+0.91 (3.48%)
At close: May 12, 2026, 4:00 PM EDT
27.09
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
27.09
+0.91 (3.48%)
At close: May 12, 2026, 4:00 PM EDT
27.09
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Name | Position |
|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO |
| Dr. Judith V. Klimovsky M.D. | Executive VP & Chief Development Officer |
| Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer |
| Dr. Mijke Zachariasse Ph.D. | VP, Head of Antibody Research Materials & Director |
| Dr. Tahamtan Ahmadi M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Experimental Medicines |
| Mr. Anthony Pagano CPA |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | 6-K | gmab_20260508x6k.htm |
| 2026-05-07 | 6-K | gmab_20260507x6k.htm |
| 2026-04-17 | 6-K | gmab_2026417x6k.htm |
| 2026-04-14 | 6-K | gmab_20260414x6k.htm |
| 2026-04-01 | 6-K | gmab_20260401xx6kx2.htm |
| 2026-03-30 | 6-K | gmab_2026330x6k.htm |
| 2026-03-23 | 6-K | gmab_20260323x6k.htm |
| 2026-03-19 | 6-K | gmab_20260319x6k1.htm |
| 2026-03-16 | 6-K | gmab_20260316xx6k.htm |
| 2026-03-09 | 6-K | gmab_20260309x6k.htm |
| Executive VP & CFO |
| Mr. Christopher Cozic | Executive VP & Chief People Officer |
| Mr. Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer |
| Mr. Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director |
| Mr. Rayne Waller | Executive VP & Chief Technical Operations Officer |